openPR Logo
Press release

Lawsuit filed for Investors in shares of Alpha and Omega Semiconductor Limited (NASDAQ: AOSL)

03-25-2020 06:52 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Alpha and Omega Semiconductor Limited (NASDAQ: AOSL) shares.

A lawsuit was filed on behalf of investors in Alpha and Omega Semiconductor Limited (NASDAQ: AOSL) shares.

An investor, who purchased shares of Alpha and Omega Semiconductor Limited (NASDAQ: AOSL), filed a lawsuit over alleged violations of Federal Securities Laws by Alpha and Omega Semiconductor Limited.

Investors who purchased shares of Alpha and Omega Semiconductor Limited (NASDAQ: AOSL) have certain options and for certain investors are short and strict deadlines running. Deadline: May 18, 2020. NASDAQ: AOSL investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

On February 5, 2020, post-market, Alpha and Omega Semiconductor Limited announced its financial results for the second fiscal quarter of 2020. Alpha and Omega Semiconductor Limited also disclosed that the U.S. Department of Justice "recently commenced an investigation into the Company's compliance with export control regulations relating to certain business transactions with Huawei and its affiliates ('Huawei')" and that "[i]n connection with this investigation, [the Department of Commerce] has requested the Company to suspend shipments of its products to Huawei . . . . Accordingly, we expect the financial performance in the March quarter will be negatively impacted by the Huawei shipment interruption and by additional professional fees incurred in connection with the investigation."

Shares of Alpha and Omega Semiconductor Limited (NASDAQ: AOSL) declined from $23.00 per share on January 8, 2017, to as low as $7.68 per share on March 13, 2020.

The plaintiff claims that between August 7, 2019 and February 5, 2020, the Defendants failed to disclose to investors that the Company's export control practices were in violation of applicable laws and regulations, that, as a result, the Company was vulnerable to regulatory scrutiny and liability, and that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Those who purchased shares of Alpha and Omega Semiconductor Limited (NASDAQ: AOSL) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Alpha and Omega Semiconductor Limited (NASDAQ: AOSL) here

News-ID: 1984642 • Views: 174

More Releases from Shareholders Foundation

Investigation for Investors in NASDAQ: APYX shares over potential Securities Law …
An investigation was announced on behalf of investors of Apyx Medical Corporation (NASDAQ: APYX) shares over potential securities laws violations by Apyx Medical Corporation. Investors who purchased shares of Apyx Medical Corporation (NASDAQ: APYX), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Apyx Medical Corporation (NASDAQ: APYX regarding its
Investigation announced for Long-Term Investors in Prudential Financial, Inc. (N …
An investigation was announced for investors in shares of Prudential Financial, Inc. (NYSE: PRU) concerning potential breaches of fiduciary duties by certain directors of Prudential Financial, Inc.. Investors who are current long term investors in Prudential Financial, Inc. (NYSE: PRU) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE:
Lawsuit filed for Investors in shares of Hanmi Financial Corporation (NASDAQ: HA …
An investor, who purchased shares of Hanmi Financial Corporation (NASDAQ: HAFC), filed a lawsuit over alleged violations of Federal Securities Laws by Hanmi Financial Corporation. Investors who purchased shares of Hanmi Financial Corporation (NASDAQ: HAFC) have certain options and for certain investors are short and strict deadlines running. Deadline: May 26, 2020. NASDAQ: HAFC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. On January 28, 2020,
Investigation announced for Investors in shares of Gossamer Bio, Inc. (NASDAQ: G …
An investigation was announced concerning possible violations of securities laws by Gossamer Bio, Inc. in connection with certain financial statements. Investors who purchased shares of Gossamer Bio, Inc. (NASDAQ: GOSS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Gossamer Bio, Inc. regarding its business, its prospects and its operations

All 5 Releases


More Releases for Alpha

Geon Network Alpha App Reaches Major Milestone
December 11, 2018 – Gibraltar - Geon Network Limited (“GEON”, “Geon Network” or “Company”) today announced that the release of its Geon Network App (“GeonApp”) available at the Apple Store and Google Play has reached its first major milestone with over 10,000 user downloads. The initial alpha Geonapp was launched for Android OS on October 25, 2018 and for iOS on October 27, 2019. These are exciting times for the
Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017, provides an overview of the Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline landscape. Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT),
Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C …
"The Report Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz Alpha 2C Adrenergic Receptor (Alpha 2 Adrenergic Receptor Subtype C4 or Alpha 2C Adrenoreceptor or ADRA2C) - Alpha-2C adrenergic receptor or ADRA2C is an alpha-2 adrenergic receptor. It mediates the
Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alpha- Antitrypsin Deficiency - Pipeline Review, H1 2017, provides an overview of the Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline landscape. Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT),
Global Alpha-Amylase Industry Report 2016
The report, ‘Global Alpha-Amylase Industry Report 2016’ provides detailed market and segment level data on the Global and Chinese consumption of Alpha-Amylase. The report provides historic, forecast and growth patterns by company, country and type/application from 2016 to 2021. This report delivers an extensive overview of Global Alpha-Amylase industry with a focus on China. It also acts as an essential tool to companies active across the value chain and to the
Alpha Trains introduces zedas®asset
Europe’s largest lessor of rail vehicles counts on PC-Soft’s solution for asset and leasing management for vehicle fleets Following an international request for proposals, Alpha Trains has now put its trust in zedas®asset. They were particularly impressed with the powerful, consistent functions for maintenance management for rail vehicle fleets, the creation of leasing contracts and the integrated mobile functionality. Upon conclusion of this project, zedas®asset will be available as an information platform